Foamix Pharmaceuticals Ltd (FOMX)

Ticker: FOMX Exchange: NMS


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Planned sale 10 Sep 2019
Value US$2,652,329.05 | Price 192.61 | Shares 99,878 (-47.7%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2019-09-11 2019-09-10 PlS Planned sale

CFO & Country Manager

99,878 -47.7%
192.61
US$2,652,329
99,878 -47.7% 192.61 US$2,652,329
2019-09-11 2019-09-09 PlS Planned sale

CFO & Country Manager

23,228 -30.6%
88.17
US$4,139,045
23,228 -30.6% 88.17 US$4,139,045
2019-08-28 2019-08-26 S Sale KAZANCHYAN ANNA Non-Executive Director
87,035 +39.6%
227.47
US$1,132,986
87,035 +39.6% 227.47 US$1,132,986
2019-07-17 2019-07-15 PlS Planned sale
808 -1.8%
2.31
US$1,866
808 -1.8% 2.31 US$1,866
2019-07-03 2019-07-01 S Sale

CLO and General Counsel

639 -1.2%
2.35
US$1,502
639 -1.2% 2.35 US$1,502
2019-07-03 2019-07-01 S Sale

Chief Scientific Officer

951 -1.5%
2.35
US$2,235
951 -1.5% 2.35 US$2,235
2019-07-03 2019-07-01 S Sale

CEO

Executive Director
3,355 -1.6%
2.35
US$7,884
3,355 -1.6% 2.35 US$7,884
2019-05-20 2019-05-20 PlS Planned sale Non-Executive Director
10,600 -18.9%
2.61
US$27,666
10,600 -18.9% 2.61 US$27,666
2019-04-03 2019-04-01 S Sale

Chief Scientific Officer

1,696 -2.6%
3.75
US$6,360
1,696 -2.6% 3.75 US$6,360
2019-04-03 2019-04-01 S Sale

CLO and General Counsel

2,519 -4.6%
3.75
US$9,446
2,519 -4.6% 3.75 US$9,446
2019-04-03 2019-04-01 S Sale

CEO

Executive Director
5,096 -2.3%
3.75
US$19,110
5,096 -2.3% 3.75 US$19,110
2019-03-06 2019-03-05 B Purchase

Chief Commercial Officer

13,440 +26.9%
3.76
US$50,534
13,440 +26.9% 3.76 US$50,534
2018-12-06 2018-12-03 S Sale Domzalski David

CEO

Executive Director
68 -0.0%
4.05
US$275
68 -0.0% 4.05 US$275
2018-12-06 2018-11-28 B Purchase Schwartz Aharon Non-Executive Director
12,200 +12.2%
3.88
US$47,373
12,200 +12.2% 3.88 US$47,373
2018-12-06 2018-11-27 B Purchase Schwartz Aharon Non-Executive Director
50,000 +100.0%
3.92
US$195,800
50,000 +100.0% 3.92 US$195,800
2018-12-06 2018-11-26 B Purchase Schwartz Aharon Non-Executive Director
50,000 +inf%
3.89
US$194,600
50,000 +inf% 3.89 US$194,600
2018-11-20 2018-11-19 S Sale Domzalski David

CEO

Executive Director
5,036 -3.3%
3.90
US$19,640
5,036 -3.3% 3.90 US$19,640
2018-11-20 2018-11-19 S Sale Howard Alvin D

VP Regulatory

Officer
3,375 -8.1%
3.90
US$13,162
3,375 -8.1% 3.90 US$13,162
2018-11-13 2018-11-08 S Sale Domzalski David

CEO

Executive Director
2,062 -1.3%
4.58
US$9,444
2,062 -1.3% 4.58 US$9,444
2018-11-13 2018-11-08 S Sale Stuart Iain

SVP R&D

Officer
683 -2.0%
4.58
US$3,128
683 -2.0% 4.58 US$3,128
2018-10-02 2018-10-01 S Sale Domzalski David

CEO

Executive Director
601 -0.4%
5.81
US$3,492
601 -0.4% 5.81 US$3,492
2018-10-02 2018-10-01 S Sale Elliott Russell P.

VP Drug Development

Officer
142 -1.1%
5.81
US$825
142 -1.1% 5.81 US$825
2018-10-02 2018-10-01 S Sale Howard Alvin D

VP Regulatory

Officer
234 -0.6%
5.81
US$1,360
234 -0.6% 5.81 US$1,360
2018-09-06 2018-09-04 S Sale Domzalski David

CEO

Executive Director
67 -0.0%
5.67
US$380
67 -0.0% 5.67 US$380
2018-08-09 2018-08-08 S Sale Domzalski David

CEO

Executive Director
8,238 -5.1%
5.68
US$46,792
8,238 -5.1% 5.68 US$46,792
2018-08-09 2018-08-08 S Sale Stuart Iain

SVP R&D

Officer
2,715 -7.3%
5.68
US$15,421
2,715 -7.3% 5.68 US$15,421
2018-07-03 2018-07-02 S Sale Domzalski David

CEO

Executive Director
602 -0.4%
5.10
US$3,070
602 -0.4% 5.10 US$3,070
2018-07-03 2018-07-02 S Sale Elliott Russell P.

VP Drug Development

Officer
142 -1.1%
5.10
US$724
142 -1.1% 5.10 US$724
2018-07-03 2018-07-02 S Sale Howard Alvin D

VP Regulatory

Officer
234 -0.6%
5.10
US$1,193
234 -0.6% 5.10 US$1,193
2018-06-04 2018-06-01 S Sale Domzalski David

CEO

Executive Director
67 -0.0%
5.26
US$352
67 -0.0% 5.26 US$352
2018-05-31 2018-05-13 S Sale Hirsch Stanley Non-Executive Director
6,164 -48.6%
5.09
US$31,369
6,164 -48.6% 5.09 US$31,369
2018-04-04 2018-04-02 S Sale Howard Alvin D

VP Regulatory

Officer
234 -0.6%
5.08
US$1,189
234 -0.6% 5.08 US$1,189
2018-04-04 2018-04-02 S Sale Elliott Russell P.

VP Drug Development

Officer
142 -1.1%
5.08
US$721
142 -1.1% 5.08 US$721
2018-04-04 2018-04-02 S Sale Domzalski David

CEO

Executive Director
602 -0.4%
5.08
US$3,058
602 -0.4% 5.08 US$3,058
2018-03-06 2018-03-02 S Sale Elliott Russell P.

VP Drug Development

817 -6.0%
6.14
US$5,016
817 -6.0% 6.14 US$5,016
2018-03-05 2018-03-01 S Sale Domzalski David

CEO

Executive Director
66 -0.0%
5.95
US$393
66 -0.0% 5.95 US$393
2018-01-18 2018-01-11 PlS Planned sale Eini Meir
5,000 -0.2%
6.33
US$31,658
5,000 -0.2% 6.33 US$31,658
2018-01-18 2018-01-10 PlS Planned sale Eini Meir
5,000 -0.2%
6.05
US$30,227
5,000 -0.2% 6.05 US$30,227
2018-01-18 2018-01-09 PlS Planned sale Eini Meir
5,000 -0.2%
6.10
US$30,520
5,000 -0.2% 6.10 US$30,520
2018-01-18 2018-01-08 PlS Planned sale Eini Meir
5,000 -0.2%
6.17
US$30,850
5,000 -0.2% 6.17 US$30,850
2018-01-18 2018-01-05 PlS Planned sale Eini Meir
5,000 -0.2%
6.58
US$32,882
5,000 -0.2% 6.58 US$32,882
2018-01-18 2018-01-04 PlS Planned sale Eini Meir
5,000 -0.2%
6.68
US$33,411
5,000 -0.2% 6.68 US$33,411
2018-01-18 2018-01-03 PlS Planned sale Eini Meir
5,000 -0.2%
6.26
US$31,310
5,000 -0.2% 6.26 US$31,310
2018-01-18 2018-01-02 PlS Planned sale Eini Meir
5,000 -0.2%
6.18
US$30,902
5,000 -0.2% 6.18 US$30,902